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Abstract
Background: We aimed to evaluate health status and associated factors in community-dwelling elderly in the
Netherlands.
Methods: Participants from a placebo-controlled double-blind randomized controlled trial conducted in the
Netherlands were invited at the time of enrolment to participate in this study. Data were collected on
comorbidities, socio-demographic background and health status, using EQ-5D-3L instrument. EQ-5D-3L summary
index values (EQ-5D-indices) was derived using Dutch tariff. Regression analysis was conducted to identify factors
associated with EQ-5D-indices and visual analogue scale (EQ-VAS).
Results: 48,634 elderly (≥65 years) were included. The most frequently reported complaint was pain/discomfort
(29.4%), but for the elder elderly (i.e. ≥85 years) it was mobility (52.9%). The proportion of persons reporting
(multiple) problems increased with age from 31.5% for 65–69 years old subjects to 65.9% for elder elderly. The
mean EQ-5D-indices and EQ-VAS decreased with age from 0.94 and 84, respectively in those 65 to 69 years old to
0.86 and 76, respectively, in ≥85 years old subjects. Increasing age, female gender, low education, geographic
factors and comorbidities were associated with impaired health status.
Conclusions: Within community-dwelling elderly large differences in health status exist. Impairment increases
rapidly with age, but health status is also associated with socio-demographic variables and comorbidities.
Trial registration: ClinicalTrials.gov, NCT00812084.
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Background
In 2050 more than 25% of the Dutch population will be
aged 65 years and older [1]. With an ageing population
and rising health expenditure, preventing illness in eld-
erly becomes more important. Measuring the health of
the population is therefore important to guide health
policy decisions, normally aimed at improving health
and reducing socioeconomic differences in health. The
EQ-5D-3L is one of most commonly applied generic
health-related quality-of-life instrument [2, 3], and is
suitable for measuring health status within an elderly
population [4, 5]. There are six publications (i.e., [6–11])
reporting quality-of-life data using the EQ-5D instru-
ment for Dutch elderly. Stolk et al. [6] reported EQ-5D-
3L-index and EQ-visual analogue scale (VAS) scores for
three age-classes (i.e. 65–69, 70–75 and ≥75 years) and
both sexes based on 254 respondents. Furthermore,
Timmers et al. [7] reported the EQ-5D-3L index values
for elderly in two age-classes of 50–69 and 70–97 years
based on 1311 respondents and using data from the
second Dutch National Survey of General Practice
(DNSGP-2) conducted in 2001 [9]. Further used
Hoeymans et al. [9] the DNSGP-2 cohort to present
the EQ-domains for elderly (1008 respondents) in
three age-classes (i.e. 60–69, 70–79 and ≥80) and
both sexes. Szende et al. [8] reported quality-of-life
(i.e. EQ-domains, EQ-5D index and EQ-VAS scores)
for two age-classes (i.e. 65–74 and ≥75 years) based
on 450 respondents, using data from the European
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Study of the Epidemiology of Mental Disorders
(ESEMeD) study collected between 2001 and 2003
[12]. Further used König et al. [10] the ESEMeD
study, to report on the EQ-domains and EQ-VAS
scores of advanced elderly (i.e., ≥75 years) in six
European countries, including the 164 Dutch responders
aged 75 and older. A more recent study (data collected in
2012), reported EQ-5D-5 L index scores for the age-
groups 60–70 and ≥70 years based on 281 respondents
[11]. Important determinants for health identified in
earlier studies were age (e.g. [8, 13–19]), gender (e.g.
[8, 13–19]) and education (e.g. [8, 13, 14, 16, 19]).
Detailed comorbidity data were in most of these stud-
ies lacking.
The aim of this study was to evaluate health status and
associated factors in community-dwelling elderly in the
Netherlands, using the EQ-5D-3L instrument.
Methods
Data collection
Data presented in the current study was collected from
the “Cost, Health status and Outcomes of community-
acquired pneumonia (CAP)” (CHO-CAP) source popu-
lation, which consisted of community-dwelling elderly
(≥65 years) in the Netherlands. The aim of the CHO-
CAP study was to prospectively collect information on
health outcomes and costs of CAP cases in a nested
matched cohort. Full details on study design are pro-
vided elsewhere [20]. The CHO-CAP study was
executed in parallel to the “Community-Acquired Pneu-
monia immunization Trial in Adults” (CAPiTA), a
placebo-controlled double-blind randomized clinical trial
evaluating the effectiveness of a 13-valent conjugate
pneumococcal vaccine in 84,496 community-dwelling
elderly in the Netherlands [21, 22]. Overall 72,074
CAPiTA participants were invited at the time of vaccin-
ation (November 2008-January 2010) to participate in
the CHO-CAP study. The remaining 12,422 subjects
(14.7%) participating in CAPiTA were vaccinated previ-
ous to the start of the CHO-CAP study. At the time of
vaccination, subjects reveived written information on the
CHO-CAP study together with a questionnaire. They
were asked to provide information on their current
health status to complement socio-demographic and co-
morbidity details collected in CAPiTA, and to return the
questionnaire together with a signed informed consent
in a pre-stamped envelope. Those who did (n = 48,634)
formed the CHO-CAP source population and were eli-
gible for participation in a nested matched cohort to
prospectively collect information on health outcomes
and costs of CAP cases. Key eligibility criteria were: no
previous pneumococcal vaccination and absence of
protocol-defined immunocompromising conditions (for
full details see [22] and Additional file 1: Section 1). In
this study we used the data collected from the CHO-
CAP source population and the self-reported comorbidi-
ties collected within the CAPiTA-trial [22].
Health status using the EQ-5D-3L instrument
The EQ-5D-3L instrument was developed by the Euroqol
group [2]. The instrument consists of two parts, the EQ-
5D descriptive system and the EQ-visual analogue scale
(VAS). The EQ-VAS records the participant’s self-reported
health on a VAS from 0 to 100, with anchor points being
labelled as “Best imaginable health state” (100) and “Worst
imaginable health state” (0). The EQ-5D-3L descriptive
system consists of five domains (i.e. mobility, self-care,
usual activities, pain/discomfort and anxiety/depression)
and three levels of functioning (i.e. no problems, some
problems or severe problems) [2]. The EQ-5D-3L health
states were scored with the Dutch value set [23], to obtain
EQ-5D-3L summary index values (EQ-5D-index) stan-
dardized from 0 (representing death) to 1 (representing
full health), with negative values representing states worse
than death [2, 23].
Socio-demographic and comorbidity data
Self-reported socio-demographic data were age, gender,
race, living situation and postal code. Self-reported co-
morbidities included asthma, diabetes with and without
use of insulin, heart disease, liver disease, lung disease,
history of splenectomy, history of stroke and/or myocar-
dial infarction and smoking behaviour. The postal code
was used to determine the geographic region of partici-
pants (i.e. east, south, north and west). The Nomencla-
ture of Territorial Units for Statistics (NUTS) was used
to determine the regions [24, 25].
Data analysis
The percentage reporting problems in one or more do-
mains of EQ-5D, the EQ-5D-indices and the EQ-VAS
were examined. Differences between age-groups were
tested using Chi-square test for categorical outcomes
and Mann–Whitney U test or Kruskal Wallis test (≥2
groups) for continuous outcomes. Results were pre-
sented by predefined age-groups (65–69; 70–74; 75–79;
80–84 and ≥85) and by sex (male and female).
Furthermore, a stepwise linear regression model was
used to identify factors associated with quality-of-life,
with EQ-5D-indices and EQ-VAS as dependent variable
respectively. Explanatory variables were age (continuous
variable), gender, education, region, smoking, having co-
morbidity x ( x stands for asthma, diabetes with and
without use of insulin, heart disease, liver disease, lung
disease and history of splenectomy) and/or having a pre-
vious cardiovascular event y ( y stands for stroke, and
myocardial infarction). Analyses were conducted using
SPSS version 22.
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Results
The CHO-CAP questionnaire was distributed to 72,074
CAPiTA-participants. The questionnaire and informed
consent were received from 48,634 subjects, correspond-
ing to a response rate of 67.5% of those invited to par-
ticipate (see Additional file 1: Figure S1).
The majority of participants were male (57%), were
aged between 65 and 74 years (69.9%), were low educated
(41.9%), lived in the west (36.6%) and had no comorbidi-
ties (54.8%), see Table 1 and Additional file 1: Table S1.
Women, the very elderly, and lower educated elderly were
underrepresented in the study population (Table 1). Non-
responders had more comorbidities than those included
in the study (see Additional file 1: Table S1).
The proportion of elderly with no problems, some
problems and severe problems of functioning by domain
and by age-group and sex is shown in Fig. 1a with
underlying data in Additional file 1: Table S2. The popu-
lation profile by age-group and sex, expressed as per-
centage reporting problems in one or several domains is
presented in Fig. 1b and in Additional file 1: Figure S2.
In most age-classes, pain/discomfort was the most
frequently reported complaint, ranging from 24.1%
(age-group 65–69) to 38.0% (age-group 80–84). Rela-
tively few respondents had problems with self-care,
ranging from 1.4% (age-group 65–69) to 5.6% (age-
group 80–84). In the eldest elderly (≥85 years), mobility
was the most frequently reported problem (52.9%), while
anxiety/depression was least frequently reported as prob-
lem (8.1%). The proportion of persons reporting prob-
lems, and the number of domains with problems is rising
with increasing age (see Figs. 1a–1b). In all age-groups
and for all five domains, women reported more problems
than men (see Figs. 1a–1b).
Mean population EQ-VAS and mean EQ-5D-index
values were 82 and 0.92, respectively. Male respondents
had both, higher EQ-VAS and higher EQ-5D-index
values than female respondents, namely 82 versus 81
and 0.93 versus 0.90 respectively, see Fig. 2 and
Additional file 1: Tables S3 and S4. Both mean EQ-
VAS and EQ-5D-index values decreased significantly
with increasing age from 84 to 0.94 in the 65–69
age-group to 76 and 0.86 in the elder elderly, respectively
(Fig. 2 and Additional file 1: Tables S3 and S4).
Next to female gender (β = −0.40) and increasing age
(β: −0.003), lower education (+0.011 for medium/+0.20
for high education), smoking (−0.021), having a comorbid-
ity (e.g. asthma: − 0.16; diabetes using insulin: −0.027)
and/or a previous cardiovascular event (stroke: −0.56;
myocardial infarct −0.29) and living in the southern region
(−0.005) were negatively associated with EQ-5D index
values (see Table 2). Similar findings were found for EQ-
VAS. For more details see Table 2.
Discussion
Within elderly people, large quality-of-life differences
exist. The proportion reporting problems was rising with
increased age, as was also the proportion of persons
reporting problems in more than one domain. For most
age-groups and both sexes, pain/discomfort was the
most frequently reported complaint. Similar to other
studies, self-care problems were reported least frequent
[9, 19, 26]. Only in the oldest elderly, mobility problems
were more frequently reported than pain/discomfort,
while anxiety/depression was the least frequent reported
problem. Similar to other studies [8–10, 13–19] female
sex was associated with more problems on each of the
five EQ-5D domains, and consequently also with a lower
EQ-5D-index compared to men. Increasing age, female
sex, lower education, smoking, having a comorbidity
and/or a previous cardio-vascular event, but also geo-
graphic factors such as living in the southern region of
the Netherlands and living in an urban area, were all as-
sociated with lower EQ-5D health status.
The use of national tariffs, different response styles
due to social and cultural background and different ref-
erence levels all influence the final EQ-5D-indices score
[10, 13, 15, 27]. According to Szende et al. [8] it is
mainly the prior living standards of a country explaining
Table 1 Characteristics of the study population compared to










65–69 years 39.9 30.6
70–74 years 30.0 24.4
75–79 years 18.3 19.5
80–84 years 8.7 13.8










a Figures from the Dutch population are derived from Statistics Netherlands
for the year 2010 [29]
b Education level: 1.2% missing data
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the observed cross-country differences in general health.
Therefore, a direct comparison with other countries is
hampered by these important cross-country differences
in background. König et al. [10], who compared the health
status of elderly in six European countries, namely
Belgium, France, Germany, Italy, the Netherlands, and
Spain, noted that the Netherlands was the country with
the lowest proportion of respondents reporting any prob-
lems. This corresponds to the findings of Konerding et al.
[13] who studied the health status in adult type 2 diabetes
patients in six European countries, and who noted that
the Dutch respondents reported fewer problems in four of
the five domains, and only Finland reported fewer prob-
lems with depression and/or anxiety. In our study, the ten-
dency of reporting problems, increased with age and was
associated with being female and having a low education,
similar to other studies (e.g. [6, 8–10, 13–16, 19, 27]).
Pain/discomfort was the most frequently reported prob-
lem, but in the eldest elderly problems with the mobility
domain occurred most frequently, similar to findings in a
a
b
Fig. 1 Profile of the population: Percentage reporting any problems per domain (a) and percentage reporting number of domains with problems
(b) by age-group and sex, respectively. * p≤ 0.001
Fig. 2 Mean population EQ-VAS and mean EQ-5D-3L-index by age-group and sex. Note: EQ-VAS and EQ-5D-3L indices were significantly different
between age-group and sex (p > 0.01)
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Dutch study of Hoeymans et al. [9]. Anxiety/depression
was reported least frequent like, in other studies [8–10].
Overall, our large sample of respondents appeared to re-
port slightly fewer problems in most domains of EQ-5D
compared to previous studies conducted in Dutch elderly
[6–8]. The relative largest differences were found for anx-
iety/depression. According to Szende et al. [8] 9.9% and
12.5% of the 65–74 years and ≥75 years old reported to be
moderately or extremely anxious or depressed, and ac-
cording to Hoeymans et al. [9] this was 11.8% (65–79
years) and 13.6% (≥80 years). In our population only 6%
reported to be moderately or extremely anxious or de-
pressed, similar to König et al. [10]. Comparing the mean
EQ-5D-index scores found in other Dutch studies, our es-
timates were slightly higher [6–8] which may be explained
from the fact that our sample consisted of a relatively fit
and healthy population participating in a clinical trial, with
more males and higher education level compared to the
general population.
Social and cultural background differences mostly
found between countries [10, 13, 15, 27] could be con-
firmed to exist also within a small country such as the
Netherlands. In particular, respondents living in Southern
Netherlands tend to have a slightly lower health status
than those living in other regions. This is a consistent
finding in many studies on within country differences in
health status [28]. The different cultural and social back-
ground and history of the Southern part of the country
seems to have an impact up to today.
Strength of our study is the large study population of
elderly persons (i.e. ≥65 years), allowing stratification by
gender and five age-groups. A further strength of the
current study is the data availability of prevalent chronic
comorbidities and/or a previous cardio-vascular event.
One of the limitations of our study was that we had a
sample with a higher percentage of men than all other
studies and furthermore our population had a higher
education level than the general population. By defin-
ition, immunocompromised persons were excluded, as this
was an exclusion criterion in the CAPiTA-trial [21, 22].
Our study population was therefore probably fitter and
healthier than the general Dutch elderly population.
Conclusion
Within community-dwelling elderly large differences in
health status exist. Impairment increases rapidly with
age, but health status is also associated with socio-
demographic variables and comorbidities.
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